CUE
Cue Biopharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
MACD Death Cross
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CUE
Cue Biopharma, Inc.
A clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body
Biological Technology
12/31/2014
01/02/2018
NASDAQ Stock Exchange
41
12-31
Common stock
40 Guest Street, Boston, MA 02135
--
Cue Biopharma, Inc., was incorporated in Delaware on December 31, 2014. The company is a clinical-stage biopharmaceutical company that designs a new class of injectable therapies to selectively directly participate in and regulate targeted, disease-associated T cells in patients. The company's vision is to translate nature's signals, or "cues," into protein therapies by generating a new class of T-cell conjugants for the selective regulation of disease-specific T-cells.
Company Financials
EPS
CUE has released its 2025 Q3 earnings. EPS was reported at -0.07, versus the expected -0.09, beating expectations. The chart below visualizes how CUE has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CUE has released its 2025 Q3 earnings report, with revenue of 2.15M, reflecting a YoY change of -35.58%, and net profit of -7.45M, showing a YoY change of 14.00%. The Sankey diagram below clearly presents CUE's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
